Literature DB >> 15048611

Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study.

I Reznik1, I Yavin, R Stryjer, B Spivak, N Gonen, R Strous, R Mester, A Weizman, M Kotler.   

Abstract

INTRODUCTION: Obsessive-compulsive (OC) symptoms have been observed in a substantial proportion of schizophrenic patients. There are some reports describing the appearance de novo or reemergence of preexisting OC symptoms under clozapine (CLZ) therapy. However, there are also reports describing a positive effect of CLZ therapy in OC schizophrenic patients. It seems that comorbid OC symptoms are common among CLZ-treated refractory schizophrenic patients and are likely to be an integral part of their illness. The complex nature of the treatment response in this group of schizophrenic patients is as yet unclear. The effects of CLZ on OC symptoms may vary, with evidence of improvement in some and worsening among others.
METHODS: The present case series study describes our experience with CLZ as a sole agent (n = 10) or in combination with serotonin reuptake inhibitors (n = 5), in schizophrenic patients with prominent OC symptomatology.
RESULTS: Systematic analysis of clinical features of our patients, as well as findings in the literature to date, led us to suggest some factors that may predict response to CLZ treatment in treatment-resistant schizophrenic patients with prominent OC symptoms: 1) schizophrenic patients who began to exhibit OC symptoms within the course of the psychotic process need and might to be successfully treated with CLZ alone; 2) when OC symptomatology preceded the development of schizophrenic process, CLZ monotherapy is inefficient and may even worsen OC symptoms; therefore, it should be treated concomitantly with specific anti-obsessive agents; 3) in both groups there is a definite dose-related pro-obsessive influence of CLZ when it is given in high doses. DISCUSSION: Further controlled investigations in a larger cohort of OC schizophrenic patients are needed to substantiate our hypothesis. OCD:Obsessive-compulsive disorder OCS:Obsessive-compulsive symptoms SRI:Serotonin reuptake inhibitors

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15048611     DOI: 10.1055/s-2004-815525

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  12 in total

1.  Diagnosis and treatment of a patient with both psychotic and obsessive-compulsive symptoms.

Authors:  Carolyn I Rodriguez; Cheryl Corcoran; Helen Blair Simpson
Journal:  Am J Psychiatry       Date:  2010-07       Impact factor: 18.112

2.  Interventions for obsessive compulsive symptoms in people with schizophrenia.

Authors:  Mohan Raj; Saeed Farooq
Journal:  Cochrane Database Syst Rev       Date:  2005

3.  Comorbidity in Schizophrenia: Conceptual Issues and Clinical Management.

Authors:  Hussain Muhammad Abdullah; Hameed Azeb Shahul; Michael Y Hwang; Stephen Ferrando
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

Review 4.  The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review.

Authors:  Christoffer Polcwiartek; Jimmi Nielsen
Journal:  Psychopharmacology (Berl)       Date:  2015-12-02       Impact factor: 4.530

5.  Does clozapine cause or worsen obsessive compulsive symptoms? An analysis and literature review.

Authors:  Stephen Bleakley; David Brown; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2011-12

6.  Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review.

Authors:  Frederike Schirmbeck; Mathias Zink
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

7.  Obsessive-compulsive disorder comorbidity: clinical assessment and therapeutic implications.

Authors:  Stefano Pallanti; Giacomo Grassi; Elisa Dinah Sarrecchia; Andrea Cantisani; Matteo Pellegrini
Journal:  Front Psychiatry       Date:  2011-12-21       Impact factor: 4.157

8.  Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors.

Authors:  Frederike Schirmbeck; Mathias Zink
Journal:  Front Pharmacol       Date:  2013-08-09       Impact factor: 5.810

Review 9.  Anxiety disorders and schizophrenia.

Authors:  Jacqueline E Muller; Liezl Koen; Seedat Soraya; Robin A Emsley; Daniel J Stein
Journal:  Curr Psychiatry Rep       Date:  2004-08       Impact factor: 8.081

Review 10.  Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment.

Authors:  Mathias Zink
Journal:  Adv Med       Date:  2014-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.